Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan across Caco-2 cell monolayers via its methylamidoxime prodrug

Pharmaceutical Research

Volumn 19, Issue 11, 2002, Pages 1689-1695

  Zhou, L ^a,b   Lee, K ^a,b   Thakker, D R ^a   Boykin, D W ^a   Tidwell, R R ^a,c   Hall, J E ^a,c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial; Caco 2 cells; Diamidine; Intestinal permeability; O methylamidoxime prodrug

Indexed keywords

2,4 BIS(4 AMIDINOPHENYL)FURAN; 2,4 BIS(4 AMIDINOPHENYL)FURAN BIS O METHYLAMIDOXIME; 2,5 BIS(4 AMIDINOPHENYL)FURAN; ANTIINFECTIVE AGENT; DB 289; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG TRANSPORT; EXTRACELLULAR CALCIUM; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TRANSCYTOSIS; ULTRAVIOLET SPECTROSCOPY;

ANTI-INFECTIVE AGENTS; BENZAMIDINES; CACO-2 CELLS; HUMANS; PERMEABILITY; PRODRUGS;

EID: 0036845742     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020957430400     Document Type: Article

References (27)

1. E. M. Lourie and W. Yorke. Studies in chemotherapy: The trypanocidal action of certain aromatic diamidines. Ann. Trop. Med. Parasitol. 33:289-304 (1939).
2. R. R. Tidwell and C. A. Bell. Pentamidine and related compounds in the treatment of Pneumocystis carinii infection. In P. D. Walzer, (ed.), Pneumocystis Carinii Pneumonia, Second Edition, Marcel Dekker, Inc., New York, 1993, pp. 561-583.
3. C. Burri and R. Brun. Human trypanosomiasis. In G. C. Cook (ed.), Manson's Tropical Diseases, WB Saunders, Philadelphia, Pennsylvania, 2002, in press.
4. A. D. M. Bryceson, J. D. Chulay, M. Mugambi, J. B. Were, G. Gachihi, C. N. Chunge, R. Muigai, S. M. Bhatt, M. Ho, H. C. Spencer, J. Meme, and G. Anabwani. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans. Roy. Soc. Trop. Med. Hyg. 79:705-714 (1985).
5. J. A. Fishman. Treatment of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42:1309-1314 (1998).
6. R. R. Tidwell, S. K. Jones, N. A. Naiman, L. C. Berger, W. B. Brake, C. C. Dykstra, and J. E. Hall. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 37:1713-1716 (1993).
7. O. Dann, H. Fick, B. Pietzner, E. Walkenhorst, R. Fernbach, and D. Zeh. Trypanocide diamidine mit drei isolierten Ringsystemen. Liebigs. Ann. Chem. 160-194 (1975).
8. B. P. Das and D. W. Boykin. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J. Med. Chem. 20:531-536 (1977).
9. D. W. Boykin, A. Kumar, J. E. Hall, B. C. Bender, and R. R. Tidwell. Anti-pneumocystis activity of bis-amidoximes bis-O-alkylamidoximes prodrugs. Bioorg. Med. Chem. Lett. 6:3017-3020 (1996).
10. E. A. Steck, K. E. Kinnamon, D. S. Rane, and W. L. Hanson. Leishmania donovani, Plasmodium berghei, Trypanosoma rhodesiense: Antiprotozoal effects of some amidine types. Exp. Parasitol. 52:404-413 (1981).
11. J. E. Hall, J. E. Kerrigan, K. Ramachandran, B. C. Bender, J. P. Stanko, S. K. Jones, D. A. Patrick, and R. R. Tidwell. Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Anti-microb. Agents Chemother. 42:666-674 (1998).
12. B. Clement and F. Jung. N-hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Drug Metab. Dis. 22:486-497 (1994).
13. S. M. Rahmathullah, J. E. Hall, B. C. Bender, D. R. McCurdy, R. R. Tidwell, and D. W. Boykin. Prodrugs for amidines: Synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan. J. Med. Chem. 42:3994-4000 (1999).
14. W. Kamm, P. Raddatz, J. Gante, and T. Kissel. Prodrug approach for alpha IIb beta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): Comparison of in vitro and in vivo data. Pharm. Res. 16:1527-1533 (1999).
15. L. Zhou. R. D. Voyksner, D. R. Thakker, C. E. Stephens, M. Anbazhagan, D. W. Boykin, J. E. Hall, and R. R. Tidwell. Characterizing the fragmentation of 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime and selected metabolites using ion trap mass spectrometry. Rapid Commun. Mass Spect. 16:1078-1085 (2002).
16. P. Artursson. Cell cultures as models for drug absorption across the intestinal mucosa. Crit. Rev. Ther. Drug Carrier Syst. 8:305-330 (1991).
17. K. Lee and D. R. Thakker. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J. Pharm. Sci. 88:680-687 (1999).
18. R. Clothier, G. Starzec, S. Stipho, and Y. C. Kwong. Assessment of initial damage and recovery following exposure of MDCK cells to an irritant. Toxicol. in Vitro 13:713-717 (1999).
19. P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. Measurement of protein using bicinchoninic acid [published erratum appears in Anal. Biochem. 63:279, 1987]. Anal Biochem. 150:76-85 (1985).
20. S. Neidle, L. R. Kelland, J. O. Trent, I. J. Simpson, D. W. Boykin, A. Kumar, and W. D. Wilson. Cytotoxicity of bis(phenylamidinium)furan alkyl derivatives in human tumour cell lines: Relation to DNA minor groove binding. Bioorg. Medicinal Chem. Lett. 7:1403-1408 (1997).
21. L. S. Gan, P. H. Hsyu, J. F. Pritchard, and D. Thakker. Mechanism of intestinal absorption of ranitidine and ondansetron: Transport across Caco-2 cell monolayers. Pharm. Res. 10:1722-1725 (1993).
22. P. Artursson and C. Magnusson. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 79:595-600 (1990).
23. L. S. L. Gan and D. R. Thakker. Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv. Drug Deliv. Rev. 23:77-98 (1997).
24. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880-885 (1991).
25. M. J. Cho, A. Adson, and F. J. Kezdy. Transepithelial transport of aliphatic carboxylic acids studied in Madin Darby canine kidney (MDCK) cell monolayers. Pharm. Res. 7:325-331 (1990).
26. G. A. Sawada, C. L. Barsuhn, B. S. Lutzke, M. E. Houghton, G. E. Padbury, N. F. Ho, and T. J. Raub. Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J. Pharmacol. Exp. Ther. 288:1317-1326 (1999).
27. P. Artursson and R. T. Borchardt. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14:1655-1658 (1997).